NASDAQ:XLO Xilio Therapeutics (XLO) Stock Price, News & Analysis → You won't believe what Citigroup just did to it's depositors (From American Alternative) (Ad) Free XLO Stock Alerts $1.05 +0.03 (+2.94%) (As of 06/7/2024 08:52 PM ET) Add Compare Share Share Today's Range$0.98▼$1.0650-Day Range$0.92▼$1.5352-Week Range$0.49▼$3.25Volume7.18 million shsAverage Volume871,449 shsMarket Capitalization$38.76 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Xilio Therapeutics alerts: Email Address Xilio Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy2.02% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$368,790 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.48) to ($1.16) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.88 out of 5 starsMedical Sector638th out of 903 stocksPharmaceutical Preparations Industry301st out of 426 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Xilio Therapeutics.Read more about Xilio Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.02% of the float of Xilio Therapeutics has been sold short.Short Interest Ratio / Days to CoverXilio Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Xilio Therapeutics has recently decreased by 8.19%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldXilio Therapeutics does not currently pay a dividend.Dividend GrowthXilio Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for XLO. Previous Next 2.6 News and Social Media Coverage News SentimentXilio Therapeutics has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Xilio Therapeutics this week, compared to 0 articles on an average week.Search Interest3 people have searched for XLO on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Xilio Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Xilio Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $368,790.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.20% of the stock of Xilio Therapeutics is held by insiders.Percentage Held by Institutions54.29% of the stock of Xilio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Xilio Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Xilio Therapeutics are expected to grow in the coming year, from ($1.48) to ($1.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xilio Therapeutics is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xilio Therapeutics is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXilio Therapeutics has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Xilio Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad American AlternativeYou won't believe what Citigroup just did to it's depositorsThe FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st This guide shows you what to do next. In a cashless society, Biden forces you to use the government's new "digital dollar"...CLICK HERE TO GET YOUR GUIDE NOW About Xilio Therapeutics Stock (NASDAQ:XLO)Xilio Therapeutics, Inc., a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors. The company also develops cytokine programs, which comprises XTX202, a tumor-activated IL-2; and XTX301, an investigational tumor-activated, engineered IL-12 molecule. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.Read More XLO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XLO Stock News HeadlinesJune 4, 2024 | americanbankingnews.comXilio Therapeutics (NASDAQ:XLO) Shares Down 2.8% May 14, 2024 | investorplace.comXLO Stock Earnings: Xilio Therapeutics Misses EPS for Q1 2024May 14, 2024 | globenewswire.comXilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial ResultsApril 17, 2024 | msn.comXilio Therapeutics (XLO) Price Target Increased by 17.86% to 5.61April 12, 2024 | stocknews.com3 Biotech Stocks to Invest In Right Now for Long-Term GainsApril 2, 2024 | investorplace.comXLO Stock Earnings: Xilio Therapeutics Beats EPS for Q4 2023April 1, 2024 | globenewswire.comXilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial ResultsMarch 29, 2024 | marketwatch.comXilio Shares Take Flight Premarket After Gilead DealMarch 28, 2024 | investorplace.comWhy Is Xilio Therapeutics (XLO) Stock up 168% Today?March 28, 2024 | marketwatch.comXilio Therapeutics Plans Private Placement, Job CutsMarch 28, 2024 | markets.businessinsider.comXilio Prices Private Placement Of $11.3 Mln Of Shares, Updates XTX202 Trial; To Axe 21% Of JobsMarch 28, 2024 | globenewswire.comXilio Therapeutics Announces $11.3 Million Private Placement Equity FinancingFebruary 28, 2024 | globenewswire.comXilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care ConferenceFebruary 27, 2024 | morningstar.comXilio Therapeutics Inc XLOJanuary 31, 2024 | finance.yahoo.comXilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology ConferenceJanuary 8, 2024 | finance.yahoo.comXilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology TherapiesDecember 28, 2023 | seekingalpha.comWerewolf Therapeutics: Still In The Race To Develop Next Generation CytokinesDecember 7, 2023 | finance.yahoo.comXilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy DataNovember 10, 2023 | msn.comXilio Therapeutics GAAP EPS of -$0.61November 9, 2023 | finance.yahoo.comXilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial ResultsNovember 8, 2023 | markets.businessinsider.comPromising Clinical Trials and Potential Therapies Propel Buy Rating for Xilio TherapeuticsNovember 3, 2023 | finance.yahoo.comXilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid TumorsOctober 31, 2023 | finance.yahoo.comXilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual MeetingSeptember 27, 2023 | finance.yahoo.comXilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual MeetingSeptember 5, 2023 | markets.businessinsider.comXilio Therapeutics Appoints Katarina Luptakova As CMOSee More Headlines Receive XLO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xilio Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today6/10/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:XLO CUSIPN/A CIK1840233 Webwww.xiliotx.com Phone857-524-2466FaxN/AEmployees73Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,400,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-153.48% Return on Assets-89.26% Debt Debt-to-Equity RatioN/A Current Ratio2.19 Quick Ratio2.19 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.34 per share Price / Book0.78Miscellaneous Outstanding Shares36,910,000Free Float34,993,000Market Cap$38.76 million OptionableNot Optionable Beta-0.07 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Rene Russo BCPS (Age 49)Pharm.D., President, CEO & Director Comp: $875.13kMr. Christopher Frankenfield (Age 42)Chief Operating Officer Comp: $704.85kDr. Katarina Luptakova M.D. (Age 48)Chief Medical Officer Comp: $591.92kMr. Kevin M. Brennan (Age 54)Senior VP of Finance & Accounting Dr. Uli Bialucha Ph.D.Chief Scientific OfficerMs. Stacey J. DavisChief Business OfficerDr. Scott Coleman Ph.D.Chief Development OfficerMore ExecutivesKey CompetitorsI-MabNASDAQ:IMABWerewolf TherapeuticsNASDAQ:HOWLProQR TherapeuticsNASDAQ:PRQRBiomea FusionNASDAQ:BMEARegulus TherapeuticsNASDAQ:RGLSView All CompetitorsInsiders & InstitutionsAtlas Venture Life Science Advisors LLCSold 1,766,432 shares on 5/6/2024Ownership: 2.690%PFG Investments LLCBought 30,000 shares on 4/22/2024Ownership: 0.087%Gilead Sciences, Inc.Bought 485,250 shares on 4/2/2024Total: $368,790.00 ($0.76/share)Venture Fund Xi L.P. AtlasSold 733 sharesTotal: $469.12 ($0.64/share)Venture Fund Xi L.P. AtlasSold 1,566 sharesTotal: $1,362.42 ($0.87/share)View All Insider TransactionsView All Institutional Transactions XLO Stock Analysis - Frequently Asked Questions Should I buy or sell Xilio Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xilio Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" XLO shares. View XLO analyst ratings or view top-rated stocks. How have XLO shares performed in 2024? Xilio Therapeutics' stock was trading at $0.55 at the start of the year. Since then, XLO stock has increased by 90.9% and is now trading at $1.05. View the best growth stocks for 2024 here. When is Xilio Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our XLO earnings forecast. How were Xilio Therapeutics' earnings last quarter? Xilio Therapeutics, Inc. (NASDAQ:XLO) announced its earnings results on Tuesday, May, 14th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.30) by $0.29. When did Xilio Therapeutics IPO? Xilio Therapeutics (XLO) raised $125 million in an initial public offering (IPO) on Friday, October 22nd 2021. The company issued 7,353,000 shares at a price of $16.00-$18.00 per share. Who are Xilio Therapeutics' major shareholders? Xilio Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Atlas Venture Life Science Advisors LLC (2.69%) and PFG Investments LLC (0.09%). Insiders that own company stock include Bain Capital Life Sciences Inv, Gilead Sciences, Inc, Rock Springs Capital Managemen and Venture Fund Xi LP Atlas. View institutional ownership trends. How do I buy shares of Xilio Therapeutics? Shares of XLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:XLO) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersYou won't believe what Citigroup just did to it's depositorsThe FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st...American Alternative | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xilio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xilio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.